| Biomarker ID | 865 |
| PMID | 22315056 |
| Year | 2012 |
| Biomarker | Erythrocyte sphingosine kinase-1 (SphK1) |
| Biomarker Basis | Concentration Based (pmol/mg) |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Downregulated in PCa (Healthy: 4.7±0.42; PCa: 2.14±0.17) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Healthy Men |
| Type of Biomarker | Diagnostic |
| Cohort | Eighty-eight patients with localised, locally advanced, or metastatic PCa were recruited into study. Age-matched controls with benign prostate hyperplasia (BPH) (n = 110) with young healthy males with the very small chance of having PCa foci (n = 20) were included in this study. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | Assays |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | SPHK1 |